Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica Stempel, Luca Lanino, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Eunice Wang, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Della Porta, Rami Komrokji, Amer Zeidan, Maximilian Stahl

Blood (2025) 146 (Supplement 1): 3865.

https://doi.org/10.1182/blood-2025-3865

Published: 2025

Journal Articles

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Tariq Kewan, Jan Philipp Bewersdorf, Luca Lanino, Ondrej Blaha, Jessica Stempel, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Talha Badar, Jaclynn Campos, Torsten Haferlach, Jaroslaw Maciejewski, Anoop Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Rami Komrokji, Maximilian Stahl, Matteo Della Porta, David Sallman, Amer Zeidan

Blood (2025) 146 (Supplement 1): 3863.

https://doi.org/10.1182/blood-2025-3863

Published: 2025

Journal Articles

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Jan Philipp Bewersdorf, Tariq Kewan, Luca Lanino, Wei Wei, Najla Al Ali, Amy DeZern, Mikkael Sekeres, Geoffrey Uy, Samuel Urrutia, Hetty Carraway, Pinkal Desai, Elizabeth Griffiths, Eytan Stein, Andrew Brunner, Christine McMahon, Rory Shallis, Joshua Zeidner, Michael Savona, Hayley Hawkins, Namrata Chandhok, Constantine Logothetis, Aram Bidikian, Theodore Getz, Gail Roboz, Benjamin Rolles, Eunice Wang, Amyah Harris, Maria Amaya, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan Madanat, Yasmin Abaza, Jaclynn Campos, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop Enjeti, Kamal Alrabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Max Stahl, Matteo Della Porta, Rami Komrokji, Amer Zeidan

Blood (2025) 146 (Supplement 1): 606.

https://doi.org/10.1182/blood-2025-606

Published: 2025

Journal Articles

Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)

Victoria Ling, Paula Marlton, John Reynolds, Mark Dawson, Robin Gasiorowski, Hannah Rose, Chun Yew Fong, Jake Shortt, Anoop Enjeti, Carolyn Grove, Joanna Nkyekyer, Nadia Munsef, Andrew Wei

Blood (2025) 146 (Supplement 1): 5210.

https://doi.org/10.1182/blood-2025-5210

Published: 2025

Journal Articles

Real-World Study Real-World Study of the Use of Azacitidine in Myelodysplasia in Australia

Anoop Enjeti, Asma Ashraf, Vincent Caillet, Arif Alam, Jonathan Robert Sillar, Francesco Castaldi, Taliesha Paine, Harold N. Keer

Blood (2022) 140 (Supplement 1): 12341–12342.

https://doi.org/10.1182/blood-2022-165534

Published: 2022

Journal Articles

Transfusion Associated Circulatory Overload in Ambulatory Transfusions

Jock Simpson, FRACP, FRCPA, Adam Hopkins, Anoop Enjeti, MD FRCP, FRCPA, MClin Epid, GradCert Bioethics

Blood (2017) 130 (Supplement 1): 1124.

https://doi.org/10.1182/blood.V130.Suppl_1.1124.1124

Published: 2017

Journal Articles

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Andrew Wei, MBBS, PhD FRACP, FRCPA, Stephen A. Strickland, MD MSCI, Gail J. Roboz, MD, Jing-Zhou Hou, MD PhD, Walter Fiedler, MD, Tara L. Lin, MD, Roland B. Walter, MD PhD, Anoop Enjeti, MD MRCP, FRCPA, MClin Epid, GradCert Bioethics, Brenda Chyla, PhD, Relja Popovic, PhD, Kaffa Fakouhi, Pooja Shah, Martin Dunbar, DRPH, MS, Tu Xu, PhD, Mack Mabry, MD, John Hayslip, MD MSCR

Blood (2017) 130 (Supplement 1): 890.

https://doi.org/10.1182/blood.V130.Suppl_1.890.890

Published: 2017

Journal Articles

Circulating Microvesicle Number, Function and Small RNA Content Vary with Age, Gender, Lipid, Hormone Profile and Smoking Status

Anoop Enjeti, Anita Ariyarajah, Angel D'Crus, Michael Seldon, Lisa Lincz

Blood (2016) 128 (22): 4951.

https://doi.org/10.1182/blood.V128.22.4951.4951

Published: 2016

Journal Articles

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Andrew Wei, Stephen A. Strickland, Gail J. Roboz, Jing-Zhou Hou, Walter Fiedler, MD, Tara L. Lin, Giovanni Martinelli, Roland B. Walter, MD PhD, Anoop Enjeti, Kaffa Fakouhi, David E. Darden, Martin Dunbar, Ming Zhu, Suresh Agarwal, Ahmed H. Salem, Mack Mabry, John Hayslip

Blood (2016) 128 (22): 102.

https://doi.org/10.1182/blood.V128.22.102.102

Published: 2016

Journal Articles

Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG)

Andrew Wei, MBBS, PhD, Ian D Lewis, MBBS, PhD, Uwe Hahn, MD, Gavin Cull, MBBS, DM, FRACP, FRCPA, Anoop Enjeti, MBBS, MD FRCPA, Philip Campbell, MBBS, FRACP, FRCPA, Simon Z. He, MBBS,FRACP,FRCPA, Mark S Hertzberg, MBBS PhDFRACP FRCPA, John F Seymour, MBBS, FRACP, PhD

Blood (2014) 124 (21): 944.

https://doi.org/10.1182/blood.V124.21.944.944

Published: 2014

Journal Articles

Circulating Microparticles in Snake Bite Patients with Microangiopathy.

Anoop Enjeti, MBBS, MD, FRCPA, Fiona Scorgie, Lisa Lincz, Simon Brown, Geoff Isbister, Michael Seldon

Blood (2008) 112 (11): 1213.

https://doi.org/10.1182/blood.V112.11.1213.1213

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndrome

Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate database

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

Trial in progress: A Phase IIb randomized clinical trial combining oral azacitidine and vididencel, a novel immunotherapy, for post-remission / maintenance therapy for adult patients with cytogenetically intermediate and high-risk Acute Myeloid Leukemia (ALLG AMLM22/D4 CADENCE)

Real-World Study Real-World Study of the Use of Azacitidine in Myelodysplasia in Australia

Transfusion Associated Circulatory Overload in Ambulatory Transfusions

Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year Outcomes

Circulating Microvesicle Number, Function and Small RNA Content Vary with Age, Gender, Lipid, Hormone Profile and Smoking Status

Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged ≥65 Years with Acute Myeloid Leukemia

Maintenance Lenalidomide for Adults Aged 18-65 Years with AML in First Complete Remission after Intensive Chemotherapy: A Phase Ib Dose-Escalation Study of the Australasian Leukemia and Lymphoma Group (ALLG)

Circulating Microparticles in Snake Bite Patients with Microangiopathy.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only